SD-101 dermal cream (3%) + SD-101 Dermal Cream (6%) + Vehicle (SD-101 0%)

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Epidermolysis Bullosa

Conditions

Epidermolysis Bullosa

Trial Timeline

Jan 6, 2014 → Jun 24, 2014

NCT ID

NCT02014376

About SD-101 dermal cream (3%) + SD-101 Dermal Cream (6%) + Vehicle (SD-101 0%)

SD-101 dermal cream (3%) + SD-101 Dermal Cream (6%) + Vehicle (SD-101 0%) is a phase 2 stage product being developed by Amicus Therapeutics for Epidermolysis Bullosa. The current trial status is completed. This product is registered under clinical trial identifier NCT02014376. Target conditions include Epidermolysis Bullosa.

What happened to similar drugs?

0 of 7 similar drugs in Epidermolysis Bullosa were approved

Approved (0) Terminated (1) Active (6)

🔄KB803 + PlaceboKrystal BiotechPhase 3

🔄Topical Beremagene GeperpavecKrystal BiotechPhase 3

🔄Open Label Topical Beremagene Geperpavec (B-VEC)Krystal BiotechPhase 3

🔄SD-101-6.0 cream + Placebo (SD-101-0.0) creamAmicus TherapeuticsPhase 3

❌SD-101-6.0 creamAmicus TherapeuticsPhase 3

🔄EB-101Abeona TherapeuticsPhase 3

🔄EB-101 Surgical application of RDEB woundsAbeona TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02014376	Phase 2	Completed	Jan 6, 2014	Jun 24, 2014	Epidermolysis Bullosa

Competing Products

13 competing products in Epidermolysis Bullosa

See all competitors

Product	Company	Stage	Hype Score
Efgartigimod	Argenx	Phase 1/2	36
KB803 + Placebo	Krystal Biotech	Phase 3	44
Topical beremagene geperpavec + Placebo gel	Krystal Biotech	Phase 1/2	29
Topical Beremagene Geperpavec	Krystal Biotech	Phase 3	37
Open Label Topical Beremagene Geperpavec (B-VEC)	Krystal Biotech	Phase 3	37
SD-101-6.0 cream + Placebo (SD-101-0.0) cream	Amicus Therapeutics	Phase 3	37
SD-101-6.0 cream	Amicus Therapeutics	Phase 3	29
SD-101 dermal cream (6%)	Amicus Therapeutics	Phase 2	24
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets	Abeona Therapeutics	Phase 1/2	22
EB-101	Abeona Therapeutics	Phase 3	30
EB-101 Surgical application of RDEB wounds	Abeona Therapeutics	Phase 3	34
VPD-737	Vyne Therapeutics	Phase 2	25
Serlopitant Tablet + Placebo Oral Tablet	Vyne Therapeutics	Phase 2	25